Scientific Program

Symposium Learning Objectives

  • Describe the evolving role of cellular therapy in lymphoma treatment;
  • Identify new targets and therapeutic agents in lymphoma treatment;
  • Recognize the appropriate circumstances in which to use different immune-oncology options in lymphoma treatment;
  • Evaluate how new scientific data affects the treatment of Hodgkin lymphoma;
  • Discuss the appropriate sequencing of agents in chronic lymphocytic leukemia (CLL) treatment based upon the latest scientific evidence;
  • Identify patients in need of central nervous system (CNS) prophylaxis using the latest guidelines;
  • Distinguish when to employ treatments for various T-cell lymphoma histologies;
  • Outline how timing affects the use of CAR-T as a therapeutic option for lymphoma.

Symposium Agenda

Friday, May 4, 2018    Nursing Session
Time Session
7:00-8:00 am REGISTRATION
8:00-8:15am Welcome and Introduction
8:15-9:30am An Overview of the Diagnosis, Prognosis and Evolving Treatments of Lymphoma

Sonali Smith, MD

9:50am–10:50am Oral Chemotherapy Adherence & Management of Toxicities

Andrew Evens, DO, MSc, FACP
Trevor Christ, PharmD, BCOP
Sarah Long, MSN, RN, CNL

10:50 – 11:50am Toxicity of Checkpoint Inhibitors

Barbara Pro, MD
Katherine Shea, PharmD, BCOP
Cory Bazany, PA-C

Friday, May 4, 2018 Afternoon EXHIBITS OPEN 1:00 pm–6:15 pm
Time Session
12:00-1:00pm REGISTRATION
1:00-1:10 pm Welcome and Introduction
1:10-1:40 pm Do Autologous Transplants Still Have a Role in the Era of CAR-T

Koen van Besien, MD, PhD

1:40-2:10 pm Small Molecules on the Horizon in Lymphoma

Andrew Evens, DO, MSc, FACP

2:10-2:40 pm Immune Evasion Mechanisms in Lymphoma

Justin Kline, MD

3:00-3:30 pm Beyond Checkpoint Inhibitors- Antibody Drug Conjugates in Lymphoma

Stephen Ansell, MD, PhD

3:30-4:00 pm Emerging Themes in FL Biology

Elias Campo, MD, PhD

4:00-5:00 pm SCIENTIFIC KEYNOTE: Biology of CLL and Translational Opportunities

John Gribben MD, DSc, FMedSci

Saturday, May 5, 2018     EXHIBITS OPEN 7:00 am–3:00 pm
Time Session
8:00-8:15 am Welcome and Introduction
8:15-8:45 am Hodgkin Lymphoma: What’s New in Frontline Management?

Ranjana Advani, MD

8:45-9:15 am Future Directions in FL

Jonathan Friedberg, MD, MMSc

9:15-9:45 am Future Directions in MCL

Timothy Fenske, MD

9:45-10:15am Future Directions in DLBCL

John P Leonard, MD

10:15–10:35 am REFRESHMENT BREAK
10:35-11:35 am Debate: Patients with indolent Lymphomas Should have Maintenance Therapy Christopher Flowers, MD, MS and Leo Gordon, MD
11:35 – 12:35pm CLINICAL KEYNOTE: Evolution of Transplants in Lymphoma: Past, Present, and Future

Julie Vose, MD, MBA

12:35-1:15 pm LUNCH
1:15-1:45 pm Sequencing of New Therapies in CLL

William Wierda, MD, PhD

1:45-2:15 pm Are We Ready for Subtype Specific Treatments in T-Cell Lymphomas

Steven Horwitz, MD

2:15-2:45 pm CNS Prophylaxis : Who, When & How?

Jeremy Abramson, MD, MMSc

2:45-3:00 pm Closing Remarks and Adjournment